<p>According to informed sources, Novo Nordisk AS, the owner of Wegovy and Ozempic, will continue to focus on business opportunities in the fields of obesity, diabetes, and their related complications. The company has viewed Metsera Inc. as a potential complementary transaction rather than a transformative acquisition. Novo Nordisk AS stated in a statement that the company will &#34;evaluate business development and acquisition opportunities that meet its return and capital allocation criteria and can further achieve its strategic goals.&#34;</p>

MTSR

<p>Novo Nordisk AS CEO will continue to focus on opportunities in the fields of obesity and diabetes after the failed acquisition of Metsera. The company stated that Metsera was viewed as a complementary transaction, and it will evaluate business development and acquisition opportunities that meet return and capital allocation criteria in the future to achieve its strategic goals</p>

竞购 Metsera 败给辉瑞之后，诺和诺德 CEO 将眼光转向新目标